RhumbLine Advisers
RCUS icon

RhumbLine Advisers’s Arcus Biosciences RCUS Stock Holding History

RhumbLine Advisers’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.22M Buy
241,492
+14,346
+6% +$310K ﹤0.01% 1385
2025
Q4 		$5.41M Buy
227,146
+17,510
+8% +$357K ﹤0.01% 1358
2025
Q3 		$2.85M Sell
209,636
-719
-0.3% -$7.48K ﹤0.01% 1716
2025
Q2 		$1.71M Buy
210,355
+27,446
+15% +$234K ﹤0.01% 1972
2025
Q1 		$1.44M Buy
182,909
+23,645
+15% +$274K ﹤0.01% 1985
2024
Q4 		$2.37M Sell
159,264
-2,571
-2% -$42K ﹤0.01% 1793
2024
Q3 		$2.47M Sell
161,835
-4,000
-2% -$63.1K ﹤0.01% 1794
2024
Q2 		$2.53M Sell
165,835
-6,838
-4% -$110K ﹤0.01% 1767
2024
Q1 		$3.26M Buy
172,673
+1,335
+0.8% +$23.1K ﹤0.01% 1651
2023
Q4 		$3.27M Buy
171,338
+1,489
+0.9% +$23.8K ﹤0.01% 1655
2023
Q3 		$3.05M Buy
169,849
+4,063
+2% +$81.6K ﹤0.01% 1630
2023
Q2 		$3.37M Sell
165,786
-295
-0.2% -$5.62K ﹤0.01% 1614
2023
Q1 		$3.03M Buy
166,081
+3,044
+2% +$58.2K ﹤0.01% 1594
2022
Q4 		$3.37M Buy
163,037
+4,682
+3% +$129K ﹤0.01% 1519
2022
Q3 		$4.14M Buy
158,355
+12,608
+9% +$333K 0.01% 1345
2022
Q2 		$3.69M Buy
145,747
+84,927
+140% +$2.08M 0.01% 1426
2022
Q1 		$1.92M Sell
60,820
-4,597
-7% -$154K ﹤0.01% 1835
2021
Q4 		$2.65M Sell
65,417
-86
-0.1% -$3.34K ﹤0.01% 1730
2021
Q3 		$2.28M Sell
65,503
-25
-0% -$778 ﹤0.01% 1832
2021
Q2 		$1.8M Buy
65,528
+17,755
+37% +$507K ﹤0.01% 2001
2021
Q1 		$1.34M Sell
47,773
-3,588
-7% -$125K ﹤0.01% 2074
2020
Q4 		$1.33M Buy
51,361
+5,126
+11% +$124K ﹤0.01% 2021
2020
Q3 		$792K Sell
46,235
-2,687
-5% -$60K ﹤0.01% 2083
2020
Q2 		$1.21M Sell
48,922
-5,436
-10% -$147K ﹤0.01% 1965
2020
Q1 		$754K Buy
54,358
+5,145
+10% +$64K ﹤0.01% 2004
2019
Q4 		$497K Buy
49,213
+354
+0.7% +$2.98K ﹤0.01% 2365
2019
Q3 		$445K Buy
48,859
+4,660
+11% +$37.4K ﹤0.01% 2384
2019
Q2 		$351K Buy
44,199
+4,664
+12% +$46.7K ﹤0.01% 2528
2019
Q1 		$494K Sell
39,535
-307
-0.8% -$3.33K ﹤0.01% 2335
2018
Q4 		$429K Buy
+39,842
New +$465K ﹤0.01% 2367

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

RhumbLine Advisers's RCUS Position: Q1 2026 in Review

RhumbLine Advisers increased its Arcus Biosciences (RCUS) stake by 6.3% in Q1 2026, buying an estimated $310K and bringing the position to 241,492 shares worth $5.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1385.

RhumbLine Advisers first reported a position in RCUS in Q4 2018 and has held it in 30 quarters since. The position peaked at $5.41M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • RhumbLine Advisers held 241,492 shares of Arcus Biosciences worth $5.22M as of Q1 2026.
  • RhumbLine Advisers bought 14,346 Arcus Biosciences shares in Q1 2026, an estimated $310K.
  • Arcus Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #1385 holding.
  • RhumbLine Advisers first reported a position in Arcus Biosciences in Q4 2018 and has held it in 30 quarters since.
  • RhumbLine Advisers's Arcus Biosciences position peaked at $5.41M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.